

University of Windsor

## Scholarship at UWindsor

---

Chemistry and Biochemistry Publications

Department of Chemistry and Biochemistry

---

1-1-2020

### The antioxidant vitamin E as a membrane raft modulator: Tocopherols do not abolish lipid domains

Mitchell DiPasquale  
*University of Windsor*

Michael H.L. Nguyen  
*University of Windsor*

Brett W. Rikeard  
*University of Windsor*

Nicole Cesca  
*University of Windsor*

Christopher Tannous  
*University of Windsor*

*See next page for additional authors*

Follow this and additional works at: <https://scholar.uwindsor.ca/chemistrybiochemistrypub>



Part of the [Biochemistry, Biophysics, and Structural Biology Commons](#), and the [Chemistry Commons](#)

---

#### Recommended Citation

DiPasquale, Mitchell; Nguyen, Michael H.L.; Rikeard, Brett W.; Cesca, Nicole; Tannous, Christopher; Castillo, Stuart R.; Katsaras, John; Kelley, Elizabeth G.; Heberle, Frederick A.; and Marquardt, Drew. (2020). The antioxidant vitamin E as a membrane raft modulator: Tocopherols do not abolish lipid domains. *Biochimica et Biophysica Acta - Biomembranes*.  
<https://scholar.uwindsor.ca/chemistrybiochemistrypub/152>

This Article is brought to you for free and open access by the Department of Chemistry and Biochemistry at Scholarship at UWindsor. It has been accepted for inclusion in Chemistry and Biochemistry Publications by an authorized administrator of Scholarship at UWindsor. For more information, please contact [scholarship@uwindsor.ca](mailto:scholarship@uwindsor.ca).

---

**Authors**

Mitchell DiPasquale, Michael H.L. Nguyen, Brett W. Rickeard, Nicole Cesca, Christopher Tannous, Stuart R. Castillo, John Katsaras, Elizabeth G. Kelley, Frederick A. Heberle, and Drew Marquardt

# The antioxidant vitamin E as a membrane raft modulator: Tocopherols do not abolish lipid domains

Mitchell DiPasquale<sup>a</sup>, Michael H. L. Nguyen<sup>a</sup>, Brett W. Rickeard<sup>a</sup>, Nicole Cesca<sup>a</sup>, Christopher Tannous<sup>a</sup>, Stuart R. Castillo<sup>a</sup>, John Katsaras<sup>b,c,d</sup>, Elizabeth G. Kelley<sup>e</sup>, Frederick A. Heberle<sup>f</sup>, Drew Marquardt<sup>a,g\*</sup>

<sup>a</sup>*Department of Chemistry and Biochemistry, University of Windsor, Windsor, Ontario, Canada*

<sup>b</sup>*Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, USA*

<sup>c</sup>*Joint Institute for Neutron Sciences, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA*

<sup>d</sup>*Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA*

<sup>e</sup>*NIST Center for Neutron Research, National Institute of Standards and Technology, Gaithersburg, Maryland, USA*

<sup>f</sup>*Department of Chemistry, University of Tennessee, Knoxville, TN, 37996, USA*

<sup>g</sup>*Department of Physics, University of Windsor, Windsor, Ontario, Canada; drew.marquardt@uwindsor.ca*

---

## Abstract

The antioxidant vitamin E is a commonly used vitamin supplement. Although the multi-billion dollar vitamin and nutritional supplement industry encourages the use of vitamin E, there is very little evidence supporting its actual health benefits. Moreover, vitamin E is now marketed as a lipid raft destabilizing anti-cancer agent, in addition to its antioxidant behaviour. Here, we studied the influence of vitamin E and some of its vitamers on membrane raft stability using phase separating unilamellar lipid vesicles with small angle scattering techniques and fluorescence microscopy. We find that lipid phase behaviour remains unperturbed well beyond physiological concentrations of vitamin E (up to a mole fraction of 0.10). Our results

are consistent with a proposed line active role of vitamin E at the domain boundary. We discuss the implications of these findings as they pertain to lipid raft modification in native membranes, and propose a new hypothesis for the antioxidant mechanism of vitamin E.


*Keywords:* Vitamin E,  $\alpha$ -tocopherol,  $\gamma$ -tocopherol, Lipid rafts, Small-angle neutron scattering, Lipid bilayer

---


## 1 **1. Introduction**

2 Vitamin E was discovered in 1922 by Evans and Bishop as a vital dietary  
3 biomolecule for mammalian reproduction. Yet, to this day its precise biolog-  
4 ical role continues to be debated [2, 3, 4]. Vitamin E refers to two families  
5 of molecules known as tocopherols and tocotrienols, each comprised of four  
6 members ( $\alpha$ ,  $\beta$ ,  $\gamma$ , and  $\delta$ ) differing in methylation of their chromanol ring (see  
7 Figure 1). Considering this somewhat minor structural difference between  
8 family members, and the fact that all species are regularly consumed in the  
9 average diet, it is remarkable that  $\alpha$ -tocopherol is the only one of the eight  
10 variants actively retained by the human body [5, 6].

11 A large body of literature advocates that vitamin E is the first line of  
12 defense for cell membranes against oxidation [8, 9]. As a result, vitamin E  
13 is commonly used as a bio-compatible preservative in the cosmetic and food  
14 industries [7]. However, and to the best of our knowledge, the role of vitamin  
15 E *in vivo* remains ambiguous. Some studies allude to a role in homeostatic  
16 processes, and deficiency of vitamin E leads to diseases such as infertility and  
17 neuromuscular dysfunction, all without elucidated mechanisms [1, 10]. The  
18 lack of good experimental evidence and the fact that vitamin E is found in



<b>Structure</b>	<b>R<sub>1</sub></b>	<b>R<sub>2</sub></b>	<b>Structure</b>	<b>R<sub>1</sub></b>	<b>R<sub>2</sub></b>
$\alpha$ -tocopherol ( $\alpha$ Toc)	CH <sub>3</sub>	CH <sub>3</sub>	$\gamma$ -tocopherol ( $\gamma$ Toc)	H	CH <sub>3</sub>
$\beta$ -tocopherol	CH <sub>3</sub>	H	$\delta$ -tocopherol	H	H



$\alpha$ -tocopherol quinone ( $\alpha$ TocQ)

Figure 1: Structures of the tocopherol members of the vitamin E family. Here we examine:  $\alpha$ -tocopherol ( $\alpha$ Toc) the species preferentially taken-up by the human body;  $\gamma$ -tocopherol ( $\gamma$ Toc) the most naturally abundant species [7]; and the stable oxidation product of  $\alpha$ Toc,  $\alpha$ -tocopherylquinone ( $\alpha$ TocQ).

19 extremely low concentrations *in vivo* [11], calls into question its antioxidant-  
 20 centric role [4].

21 It is not surprising that vitamin E properties are propagated by industry  
 22 and health professionals that advocate for the sale of dietary supplements.  
 23 Across North America, an estimated sixty percent of middle-to-late-aged  
 24 adults consume vitamins, including vitamin E, while sufficient recommended  
 25 amounts can generally be obtained from a balanced diet [12]. Nutrition

26 companies offer a variety of vitamin E supplements ranging from pure RRR-  
27  $\alpha$ -tocopherol to “natural” mixtures containing all of the tocopherol family  
28 members, often in amounts ranging from 3 to 30 times the recommended  
29 daily intake [7]. While the health benefits of sufficient dietary antioxidants  
30 are well documented, vitamin E is also marketed for promoting cardiovascular  
31 health and as an anti-cancer agent [13, 14].

32 The rationale for vitamin E as an anti-cancer agent is predicated on a  
33 proposed mechanism of membrane raft destabilization [15]. Cell membranes  
34 have been implicated in a vast array of cellular processes, which can often  
35 be facilitated by the lateral organization of lipids and proteins into micro  
36 and nanoscale “rafts” [16, 17]. It is thought that certain varieties of cancer  
37 cells, particularly prostate and breast, possess more robust lipid rafts that  
38 can be destabilized through cholesterol depletion by raft-modulating agents  
39 such as methyl- $\beta$ -cyclodextrin [18, 15, 19]. This hypothesis has thus inspired  
40 many studies investigating the potential anti-cancer effects of vitamin E.  
41 Notably, Yang et al. have suggested that high-dose supplementation of  $\gamma$ - and  
42  $\delta$ - tocopherols inhibits tumorigenesis, while  $\alpha$ -tocopherol does not [20, 21, 22].  
43 Conversely, clinical trials involving  $\alpha$ -tocopherol supplementation indicate an  
44 increased risk for developing prostate cancer in healthy men [14, 13].

45 Observations of membrane rafts have been elusive in live cells, presumably  
46 due to their proposed small size and transient nature, in addition to the  
47 inherent complexity of biological membranes [23, 24]. More recently, lipid  
48 domains on the order of 40 nm in size were observed in living bacteria [25].  
49 Three-component lipid mixtures mimicking the outer leaflet of eukaryotic  
50 plasma membranes are commonly used as model systems for the study of

51 lipid rafts [26, 27]. Specifically, vesicles composed of high- and low-melting  
52 lipids, and cholesterol are thermodynamically unstable and demix into a  
53 cholesterol-rich liquid ordered ( $L_o$ ) phase that coexists with a cholesterol-  
54 poor liquid disordered ( $L_d$ ) phase. These structures are compatible for study  
55 by a range of biophysical techniques, including small-angle neutron and X-ray  
56 scattering [28], and fluorescence microscopy [29, 30, 31].

57 In the current study we looked at how vitamin E affects lipid membranes,  
58 and if its behaviour is consistent with raft-disrupting anti-cancer mechanisms,  
59 in the hope of gaining a better understanding of vitamin E supplementation.

## 60 **2. Materials and Methods**

### 61 *2.1. Materials*

62 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (16:0/16:0 PC, DPPC), 1,2-  
63 dipalmitoyl-d62-sn-glycero-3-phosphocholine (16:0[d31]/16:0[d31] PC, d62-  
64 DPPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (18:1/18:1 PC, DOPC), and  
65 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B  
66 sulfonyl) (LR-DPPE) were purchased from Avanti Polar Lipids, Inc. (Al-  
67 abaster, AL). Cholesterol, DL-all-rac- $\alpha$ -tocopherol ( $\alpha$ -tocopherol,  $\alpha$ Toc), (R,R,R)-  
68  $\gamma$ -tocopherol ( $\gamma$ -tocopherol,  $\gamma$ Toc), D- $\alpha$ -tocopherylquinone ( $\alpha$ -tocopherylquinone,  
69  $\alpha$ TocQ), and sucrose were purchased from Sigma-Aldrich (St. Louis, MO).  
70 Naphtho-[2,3-a]pyrene (naphthopyrene) was purchased from TCI America  
71 (Tokyo, Japan). 99.9 % D<sub>2</sub>O was purchased from Cambridge Isotopes (An-  
72 dover, MA). All reagents were used without further purification.

73 *2.2. SANS Sample Preparation*

74 *2.2.1. Selection of Lipid Composition*

75 All experiments were performed using a mixture of DPPC/DOPC/Chol  
76 at a mole ratio of 37.5/37.5/25, respectively. This composition contains a  
77 1:1 ratio of high- and low-melting lipids such that the area fractions of  $L_o$   
78 phase and  $L_d$  phase domains are approximately equal. The phase behaviour  
79 of this composition has carefully been characterized by different techniques  
80 in a number of previous studies, thereby offering a reliable foundation for  
81 this work [30, 32, 33].

82 *2.2.2. Preparation of Unilamellar Vesicles*

83 Well-established protocols were followed to prepare unilamellar vesicles  
84 (ULVs) for scattering measurements. In brief, lipid mixtures were prepared  
85 by transferring desired volumes of stock solutions in HPLC-grade chloro-  
86 form to a scintillation vial using a glass syringe (Hamilton USA, Reno, NV).  
87 Lipid films were formed through chloroform evaporation under a gentle argon  
88 stream, followed by trace solvent removal *in vacuo* for >12 hours. The films  
89 were hydrated to 20 mg/ml by the addition of a 34.6% D<sub>2</sub>O/H<sub>2</sub>O mixture,  
90 and incubated for 30 minutes at 50 °C prior to the formation of a multilamel-  
91 lar vesicle (MLV) suspension by vortexing. The ratio of D<sub>2</sub>O/H<sub>2</sub>O was used  
92 to replicate the contrast matching scheme described by Heberle et al., such  
93 that the scattering length density of the aqueous solvent is simultaneously  
94 matched to the that of the lipid headgroup and average hydrocarbon chain  
95 compositions. This contrast matching scheme minimizes scattering contri-  
96 butions arising from transverse (i.e., normal to the plane of the bilayer)  
97 scattering length density variation, and emphasizes scattering contributions



98 arising from in-plane heterogeneity (i.e., demixing of saturated and unsat-  
99 urated chains) [34]. The MLV suspension was subjected to 5 freeze/thaw  
100 cycles between -80 °C and 50 °C, followed by vortexing at 50 °C. ULVs were  
101 then prepared by 31 passes through a hand-held miniextruder equipped with  
102 a 50 nm pore-diameter polycarbonate filter (Avanti Polar Lipids, Alabaster,  
103 AL) and heated to 50 °C. Extruded vesicles were characterized by dynamic  
104 light scattering on a Malvern ZetaSizer Nano ZS (Malvern Panalytical, Ltd.,  
105 Malvern, UK).

### 106 *2.3. Characterization of Phase Separation by Contrast-Matched SANS*

107 Neutron scattering experiments were performed at the Very Small-Angle  
108 Neutron Scattering (NG3-VSANS) instrument located at the National Insti-  
109 tute of Standards and Technology Center for Neutron Research (NIST-CNR).  
110 The white beam option was configured to use a neutron wavelength of 5.3  
111 Å with a  $\Delta\lambda/\lambda$  of 40%. Data were collected using two detector carriages  
112 positioned at sample-to-detector distances of 5.4 m and 13 m. This single  
113 configuration and large wavelength spread results in lower q-resolution, but  
114 allows for higher flux at the point of the sample, and thus shorter count  
115 times. In this case, good quality data in a scattering vector range of  $0.009$   
116  $\text{Å}^{-1} < q < 0.5 \text{ Å}^{-1}$  were acquired in three minutes.

117 Additional experiments were performed at the CG-3 Bio-SANS instru-  
118 ment of the High Flux Isotope Reactor (HFIR) located at Oak Ridge Na-  
119 tional Laboratory (ORNL). Data were taken at a sample-to-detector distance  
120 of 15.5 m using 6 Å wavelength neutrons (fwhm 15%). A total scattering  
121 vector of  $0.003 \text{ Å}^{-1} < q < 0.8 \text{ Å}^{-1}$  was collected using a two-dimensional  
122 (1 m × 1 m)  $^3\text{He}$  position-sensitive detector (ORDELA, Inc., Oak Ridge,

123 TN) with  $192 \times 256$  pixels in combination with a  $1 \text{ m} \times 0.8 \text{ m}$  wing detector  
124 comprised of  $160 \times 256$  pixels and rotated by  $1.40^\circ$ .

125 ULV suspensions of  $20 \text{ mg/ml}$  were loaded into  $1 \text{ mm}$  path-length banjo  
126 cells (Hellma USA, Plainview, NY) and mounted in a Peltier temperature-  
127 controlled cell holder with  $\approx 1^\circ\text{C}$  accuracy. Samples were measured at 7 tem-  
128 peratures, ranging from the two-phase ( $L_o / L_d$ ) liquid coexistence regime at  
129 lower temperatures through to the uniformly melted  $L_d$  phase at higher tem-  
130 peratures. At a minimum, samples were permitted to equilibrate at each tem-  
131 perature for 20 minutes prior to measurement. Data were reduced, stitched,  
132 and corrected for detector pixel sensitivity, dark current, sample transmis-  
133 sion, and background scattering from water using ORNL's Mantid software  
134 (BioSANS) [35] or the appropriate Igor Pro macros (VSANS) provided by  
135 NIST-CNR [36].

136 The resulting data were analyzed in a model-independent manner using  
137 the Porod invariant to represent the total scattering intensity [37]:

$$Q = \int_0^\infty q^2 I(q) dq \quad (1)$$

138 With the contrast matching scheme used here,  $Q$  to a first approximation  
139 is only dependent on the area fraction of the  $L_o$  phase ( $a_{L_o}$ ) and the difference  
140 in contrast between the  $L_o$  and  $L_d$  domains ( $\Delta\rho$ ) [38]:

$$Q \approx a_{L_o}(1 - a_{L_o})\Delta\rho^2 \quad (2)$$

141 Since neutron contrast depends on how strongly the deuterated and proti-  
142 ated lipids are segregated, SANS measurements can detect changes in domain  
143 area fraction ( $a_{L_o}$ ) or a change in the partitioning of the lipids between the

144 coexisting phases. For example, either a decrease in domain area fraction,  
145 or reduced partitioning of saturated and unsaturated lipids between the two  
146 phases, will cause a decrease in the total scattering according to Eq. 2. Both  
147 of these features imply a destabilization of lipid domains.

#### 148 *2.4. Bilayer Structure from SAXS*

149 Small angle X-ray scattering (SAXS) experiments were performed on the  
150 same samples measured by SANS. ULVs at a concentration of 10 mg/ml were  
151 measured using a Rigaku BioSAXS-2000 (Rigaku Americas, The Woodlands,  
152 TX) equipped with a Pilatus 100K detector and an HF007 rotating copper  
153 anode source. All samples were measured above the phase transition tem-  
154 perature (50 °C) to ensure well mixed bilayers. Multiple measurements were  
155 obtained for each sample, and samples were monitored for radiation damage  
156 before averaging. Resulting form factors in the scattering vector range of  
157  $0.04 \text{ \AA}^{-1} < q < 0.6 \text{ \AA}^{-1}$  were background-corrected using PRIMUS [39] and  
158 modeled using the Global Analysis Program (GAP) developed by Pabst et al.  
159 [40, 41].

#### 160 *2.5. Preparation and Fluorescence Imaging of Giant Unilamellar Vesicles*

161 Giant unilamellar vesicles (GUVs) suitable for epifluorescence microscopy  
162 were generated using a modified electroformation protocol as described by  
163 Konyakhina and Feigenson [42, 43]. In brief, lipid mixtures with and without  
164 a vitamin E mole fraction of 0.10 ( $\chi = 0.10$ ) were mixed in chloroform and  
165 combined with fluorescent probes at predefined mole ratios. The mixture  
166 was then spread evenly onto a conductive indium tin oxide (ITO)-coated  
167 slide (Delta Technologies, LTD., Loveland, CO). The fluorescent probes

168 ( $\chi_{LR-DPPE} = 0.005$  and  $\chi_{naphthopyrene} = 0.01$ ) were chosen based on their  
169 known lipid phase partitioning behavior [44]. Solvent was removed by overnight  
170 drying *in vacuo* for >12 hours. GUVs were then formed in 100 mmol/L  
171 aqueous sucrose by heating for 1 h at 50 °C with electroformation by a 10  
172 Hz sinusoidal current with a peak-to-peak amplitude of 1 V. The samples  
173 were gradually cooled to room temperature over 10 h using a Digi-Sense  
174 benchtop temperature controller (Cole Parmer, Vernon Hills, IL) to mini-  
175 mize kinetically-trapped domain artifacts. GUVs were transferred to a glass  
176 coverslip enclosed by a silicon gasket, sealed by a glass slide, and allowed to  
177 settle for 1 h prior to imaging. All samples were imaged at ambient tempera-  
178 ture within 24 h of preparation using an inverted epifluorescence microscope  
179 (Leica DMI6000, Wetzlar, Germany). LR-DPPE was detected using a Texas  
180 Red filter cube (ex. 594 nm / em. 598 nm) and naphthopyrene was detected  
181 using a DAPI filter cube (ex. 357 nm / em. 459 nm). Care was taken to  
182 prevent light-induced phase separation by minimizing illumination intensity  
183 and exposure [45, 46]. Resulting images were artificially recoloured for pub-  
184 lication using the Leica LAS X software to improve accessibility for readers  
185 with vision impairment.

### 186 **3. Results and Discussion**

#### 187 *3.1. Tocopherol does not affect bilayer structure*

188 Phase separating ULVs suspended in water were heated to 50 °C to en-  
189 sure a uniform distribution of the lipids, thus ensuring a bilayer of uniform  
190 thickness suitable for structural studies by SAXS. To quantify any differences  
191 in bilayer structure, the scattering form factors were modeled using the GAP

192 program to determine physical parameters [40, 41]. GAP models an electron  
193 density profile of the bilayer by parameterizing three Gaussians, one for each  
194 electron-rich head group and one for the hydrocarbon region. As X-rays are  
195 sensitive to the electron-rich phosphates in the lipid head groups, we report  
196 the headgroup-headgroup distance of the bilayers ( $d_{HH}$ ) from the optimized  
197 modelled form factor. Note,  $d_{HH}$  is directly determined and requires no sub-  
198 sequent calculations or assumptions about the system. As explained in the  
199 SI, due to the complexity of the multi-component systems, some parameters  
200 were fixed to refine the fit.

201 Table 1 summarizes  $d_{HH}$  for each composition explored and additional fit  
202 parameters are shown in Table S1 of the Supplementary Material. Mea-  
203 sured headgroup-headgroup distances for DPPC/DOPC/Chol are consis-  
204 tently within 2% of previously reported values [33, 47, 48]. Interestingly,  
205 up to a mole fraction of 10% tocopherol, the transverse bilayer structure is  
206 not significantly perturbed. The slight thinning of the bilayer upon addi-  
207 tion of tocopherol is likely an artifact of fixing the width of the Gaussian  
208 describing the headgroup,  $\sigma_H$ . Due to the orientation of tocopherol in the  
209 membrane, with its chromanol headgroup residing at the hydrophilic inter-  
210 face [49, 50, 51], additional electron density will be present slightly inside the  
211 headgroup Gaussian, which is best described by a wider  $\sigma_H$  and an asym-  
212 metric Gaussian. Since the GAP program cannot parameterize for skewed  
213 Gaussians, it compensates for this distribution by shifting the position of the  
214 headgroup,  $z_H$ , closer to the bilayer center. This trend is most dramatic for  
215  $\alpha$ TocQ, though only 1.4 Å thinner, where the electron-rich benzoquinone  
216 head contributes to a greater proportion of the electron density within the

217 bilayer, just beyond the phosphate group. Indirectly, this suggests that both  
 218  $\gamma$ Toc and  $\alpha$ TocQ are likely to localize in the membrane similarly to  $\alpha$ Toc,  
 219 consistent with past neutron diffraction observations [51].

Table 1: Bilayer thickness, represented by the headgroup-headgroup distance,  $D_{HH}$ , as a function of percent tocopherol. Parameters were derived from modelling small angle X-ray scattering data, with uncertainties defined as 2%

<b>Composition</b>	<b><math>D_{HH}</math> (<math>\text{\AA}</math>)</b>
DPPC/DOPC/Chol	$39.9 \pm 0.8$
+ 2 % $\alpha$ Toc	$39.2 \pm 0.8$
+ 5 % $\alpha$ Toc	$39.2 \pm 0.8$
+ 2 % $\gamma$ Toc	$39.7 \pm 0.8$
+ 10 % $\gamma$ Toc	$39.2 \pm 0.8$
+ 2 % $\alpha$ TocQ	$39.1 \pm 0.8$
+ 10 % $\alpha$ TocQ	$38.5 \pm 0.8$

The following parameters were fixed based on physical considerations as described in the SI [47]: width of Gaussian describing the phosphatidylcholine headgroup,  $\sigma_H = 3.0 \text{ \AA}$ , and amplitude of the Gaussian describing the hydrocarbon tail, relative to that of the headgroup,  $\rho_C = -1.0$ . All fit parameters are tabulated in Table S1.

220 *3.2. Tocopherol destabilises microscopic phase separation*

221 GUVs are widely used as models for probing the existence and mor-  
 222 phology of phase separation at the microscopic level. In this study, the  
 223 DPPC/DOPC/Chol 37.5/37.5/25 system displays robust hemispherical do-  
 224 mains that can be visualized by the selective partitioning of naphthopyrene  
 225 and LR-DPPE into the  $L_o$  and  $L_d$  membrane environments, respectively (Fig.

226 2A) [44]. At ambient temperature, the addition of  $\chi = 0.10$   $\alpha$ - (Fig. 2B) or  
227  $\gamma$ - tocopherol (Fig. 2C) appears to abolish the phase separation, although  
228 the presence of domains smaller than the optical resolution limit ( $\approx 200$  nm)  
229 cannot be ruled out. Similar suppression of phase separation is observed  
230 by heating the system to a point where the mixing entropy, which favours  
231 the random arrangement of lipids, dominates over the non-ideal enthalpic  
232 contribution to free energy, and results in increased acyl chain disorder and  
233 increased lateral lipid diffusion.

234 In contrast to  $\alpha$ - and  $\gamma$ -tocopherol, the presence of  $\alpha$ -tocopherylquinone  
235 ( $\alpha$ TocQ), even up to a mole fraction of 0.10, does not appear to change the  
236 phase behaviour (Fig.2D).

### 237 *3.3. Domain perturbations described by SANS*

238 Contrast-matched SANS is a powerful tool to probe the lateral orga-  
239 nization of lipids along the bilayer and from SANS one is able to extract  
240 precise structural features. An example of this is provided by the model-  
241 ing of SANS data to determine domain size in refs [34, 52]. According to  
242 the work of Pencer et al., due to the dependence of the scattering function  
243 on contrast, lateral segregation of deuterated and protiated lipids into do-  
244 mains yields a scattering contribution that directly correlates to the extent  
245 of phase separation. With this experimental design, data can be reduced to a  
246 model-independent scalar quantity known as the Porod invariant,  $Q$  (Eq. 2)  
247 representing the total scattering arising from system contrast [38]. Using this  
248 approach, phase behaviour can easily be obtained from the low  $q$ -resolution  
249 scattering of laterally heterogeneous vesicles. Using a DPPC/DOPC/Chol  
250 system, Figure 3(A) shows the difference in scattering obtained by varying




Figure 2: Fluorescence microscopy of GUVs composed of (A) DPPC/DOPC/Chol; (B) +  $\chi = 0.10$   $\alpha$ Toc; (C) +  $\chi = 0.10$   $\gamma$ Toc and (D) +  $\chi = 0.10$   $\alpha$ TocQ. Naphthopyrene (blue) preferentially localizes in the  $L_o$  phase and LR-DPPE (red) in the  $L_d$  phase. Subsequent acquisitions of each fluorophore are colour-merged to highlight the different phases. Phase separation is observed in the undoped system (A) and in the presence of  $\alpha$ TocQ (D), but is not observed with  $\alpha$ Toc (B) or  $\gamma$ Toc (C).

Temperature = 21 °C. Scale bar = 25  $\mu$ m.

251 the q-resolution. High q-resolution data were collected at CG3-BioSANS  
 252 (HFIR, ORNL) and low q-resolution data at NG3-VSANS (NCNR). By ex-  
 253 tracting the Porod invariant and normalizing to a relative scale bound by the  
 254 highest contrast (lowest temperature) and lowest contrast (highest tempera-  
 255 ture), the temperature dependence of phase separation between samples can  
 256 be directly compared (Fig. 3B). From this normalized scattering intensity,  
 257  $Q_{norm}$ , it can be shown that the decay in scattering intensity is not depen-  
 258 dent on q-resolution. The low and high q-resolution data were obtained from  
 259 different sample preparations of the same composition, and differences in



260 samples may account for the small variations in decay at 25 °C. The low q-  
261 resolution “white beam” of VSANS allows for rapid data collection resulting  
262 in high sample throughput. However, due to the large wavelength spread,  
263  $\frac{\Delta\lambda}{\lambda}$ , structural features are lost, as demonstrated by comparing Figure 3(A)  
264 and the inset to Figure 3(A). As a result, modeling the domain size in a fash-  
265 ion similar to Bolmatov et al. is not a viable approach [53]. Nevertheless,  
266 the use of the VSANS’ “white beam” option provides a 4x increase in flux  
267 over conventional SANS experiments and is particularly useful for measuring  
268 labile samples that may change during the data acquisition time required to  
269 collect good quality data on a conventional SANS instrument.

270 Low q-resolution SANS curves featured in Figure 4 show a decrease in  
271 scattering intensity as a function of increasing temperature. Phase separa-  
272 tion in samples were confirmed to be thermodynamically stable and free of  
273 hysteresis effects by measuring sequential heating and cooling scans (Figure  
274 S2).

275 The decrease in scattering intensity is a result of less contrast between the  
276 lipid phases as they become more miscible, induced by increasing temperature  
277 and the addition of tocopherol. Phase separation has been proposed to have  
278 biological implications, particularly at the level of protein regulation [54, 55].  
279 Though we must be cautious in extrapolating results from vesicle models  
280 to biology, this result may suggest that less distinction in the properties of  
281 the two phases may diminish the efficacy of segregating membrane proteins  
282 solely on the basis of phase preference.

283 While valuable, the SANS form factors (Fig.4) do not offer a clear com-  
284 parison between the different lipid compositions. By reducing the data to




Figure 3: Comparison of different q-resolution SANS data. (A) Low resolution scattering from DPPC/DOPC/Chol as a function of temperature from 15 °C (blue) to 45 °C (red). The inset shows high q-resolution data from the same sample composition. A logarithmic scale is used to emphasize the difference between the form factors. (B) Normalized scattering intensity (Q) as a function of temperature extracted from both the low- (black circles) and high-resolution (grey squares). Error is defined as one standard deviation and error bars are smaller than the data markers.

285 Q and normalizing each sample with the bounds of the DPPC/DOPC/Chol  
 286 system in the absence of tocopherol, we are able to directly compare changes  
 287 to the membrane by the presence of tocopherol. These trends are shown in  
 288 Figure 5, which represents the structurally-independent total scattering from  
 289 domains as a function of temperature. Remarkably, there is little apprecia-  
 290 ble deviation in total scattering for samples containing  $\chi = 0.02$  or  $\chi = 0.05$




Figure 4: SANS intensity as a function of temperature and membrane composition. ULVs of DPPC/DOPC/Chol and DPPC/DOPC/Chol + $\alpha$ Toc, + $\gamma$ Toc, and + $\alpha$ TocQ at a mole fraction of 0.10 were measured at (15, 18, 25, 31, 34, 37, and 45) °C. The presence of different tocopherols modulates both scattering intensity and the rate of intensity decay. Plots show  $0.009 \text{ \AA}^{-1} < q < 0.05 \text{ \AA}^{-1}$  to highlight the difference in scattering at low  $q$ .

291  $\alpha$ Toc or  $\gamma$ Toc, however, domains appear to destabilize at higher ( $\chi = 0.10$ )  
 292 concentrations. Moreover, due to the strong similarity between the effects  
 293 of  $\alpha$ Toc and  $\gamma$ Toc on phase behaviour, we suggest that this is likely not a  
 294 determinant in biological selectivity for  $\alpha$ Toc.

295 It is noteworthy that even at a high concentration, Q is not totally abol-




Figure 5: Normalized total scattering (Q) measured by low q-resolution SANS. DPPC/DOPC/Chol samples containing  $\chi = 0$  (■; black),  $\chi = 0.02$  (○; green),  $\chi = 0.05$  (△; blue) and  $\chi = 0.10$  (◇, orange) of the vitamin E analogues  $\alpha$ Toc (top),  $\gamma$ Toc (middle), and  $\alpha$ TocQ (bottom). The mixtures were measured in the temperature range of 15-45 °C. Smooth curves were added to assist in visualizing trends in the data. Error is defined as one standard deviation and error bars are smaller than the data markers.

296 ished, indicating that the membrane may not be homogeneous, but still con-  
297 tains nanoscale lateral heterogeneities. More likely, however, residual scat-  
298 tering intensity is a remnant of the inability to contrast match contributions  
299 from both lateral and transverse contrast simultaneously.

300 There are many proposed mechanisms of nanodomain stabilization, in-  
301 cluding coupling of bilayer composition and curvature inducing a microemul-  
302 sion [56], line tension competing with a long range repulsive force [57], or  
303 Ising-like critical fluctuations [58]. Our data do not allow us to discriminate  
304 between these or other proposed theories of nanodomain stabilization. The  
305 most recently reported mechanism that has been suggested for vitamin E is  
306 that of a linactant-induced microemulsion [34, 59, 60, 61].

307 Muddana et al. previously explored the phase activity of  $\alpha$ Toc using  
308 coarse-grained Molecular Dynamics simulations to complement GUV mi-  
309 croscopy observations [60]. Their results indicate  $\alpha$ Toc localizes to the do-  
310 main interface, thereby acting as a linactant to destabilize macrodomains.  
311 We must stress that with SANS we cannot comment on the localization of  
312 individual molecules, and though we cannot directly lend support to the  
313 mechanism proposed by Muddana et al., our results are qualitatively consis-  
314 tent. In fact, one cannot claim for certain a linactant mechanism without  
315 verifying that the molecule preferentially localizes to the phase boundary.  
316 Our DPPC/DOPC/Chol system is classified as a Type II phase-separating  
317 mixture, which produces macroscopic hemispherical domains [26]. The large  
318 domains result from high line tension due to a large hydrophobic thickness  
319 mismatch between the coexisting phases [34, 62, 63]. The linactant theory  
320 postulates that the addition of molecules that partition preferentially to do-

321 main interfaces should lower the line tension and result in smaller domains.  
322 This theory has gain more traction recently as Yang et al. showed that  $\alpha$ Toc  
323 can minimize line tension at domain boundaries as a means of protecting  
324 against HIV gp41-mediated membrane fusion [61].

325 In the case of  $\alpha$ TocQ, the effect on lipid segregation is significantly less  
326 pronounced. In fact, there is an apparent increase in domain stability with  
327 even small amounts of  $\alpha$ TocQ. Taken together, our results could lead to  
328 speculation of a physiological benefit for an effective membrane antioxidant.  
329 Phase boundaries have been identified as a favourable site for membrane  
330 permeation [64]. As suggested by Yang et al., tocopherol stabilizes domain  
331 interfaces to produce a less permeable boundary [61]. Considering the theory  
332 described by Cruzeiro-Hansson and Mouritsen [65] and refined by Cordeiro  
333 [66], a reduction in bilayer thickness mismatch reduces the possibility of pore  
334 mediated permeation of oxidants. In the instance of membrane oxidation, the  
335 initial formation of hydroperoxide lipids promotes the formation of domain  
336 interfaces [67], which would be stabilized by present tocopherols. As oxida-  
337 tion progresses, chemistry evolves the stable products  $\alpha$ -tocopherylquinone  
338 and truncated lipids which together drives phase separation [68]. This final  
339 increase in lipid raft stability is a potential signal to recruit key proteins to  
340 recover or terminate the cell. In this manner, tocopherol would offer a new  
341 dimension to its antioxidant activity by protecting the cell membrane from  
342 oxidation induced lateral organization and permeation.

343 Again, we must be cautious in extending these observations into the phys-  
344 iological realm. The phase modulation we observe arises at vitamin E con-  
345 centrations that have not been physiologically observed, even with extensive

346 supplementation [11].

#### 347 **4. Conclusion**

348 In an effort to begin testing a proposed mechanism of vitamin E's anti-  
349 cancer action, we reported on the effect that different members of the vitamin  
350 E family have on lipid domains. Data were collected using two different  
351 SANS configurations and microscopy, all of which yield consistent results  
352 with regards to vitamin E's influence on membrane organization. Though  
353 its phase behaviour is consistent with its membrane-protective role when in  
354 concentrations ranging between  $0.0001 < \chi < 0.004$  [11], the lack of lipid  
355 domain response at  $\chi = 0.02$   $\alpha$ Toc or  $\gamma$ Toc strongly suggests that increased  
356 vitamin E intake does not destabilize domains, as has been proposed. With  
357 regard to the complexity and variety of phase-active compounds in the native  
358 membrane, it seems unlikely that a local mole fraction of vitamin E greater  
359 than 0.02 is a definite actuator of domain stability. Therefore, the present  
360 work scrutinizes the validity of supplementing vitamin E as a presumed anti-  
361 cancer agent.

#### 362 **Acknowledgements**

363 We acknowledge the support of the National Institute of Standards and  
364 Technology, U.S. Department of Commerce in providing access to the NG3  
365 VSANS instrument through the Center for High Resolution Neutron Scatter-  
366 ing, a partnership between the National Science Foundation and the National  
367 Institute of Standards and Technology under Agreement DMR-1508249. Cer-  
368 tain commercial equipment or materials are identified in the paper to foster

369 understanding. Such identification does not imply recommendation or en-  
370 dorsement by the National Institute of Standards and Technology, nor does  
371 it imply that the materials or equipment identified are necessarily the best  
372 available for the purpose. A portion of this research used resources from the  
373 CG3 BioSANS instrument at the High Flux Isotope Reactor, a DOE Office  
374 of Science User Facility operated by the Oak Ridge National Laboratory.  
375 J.K is supported through the Scientific User Facilities Division of the De-  
376 partment of Energy Office of Science, sponsored by the Basic Energy Science  
377 Program, Department of Energy Office of Science, under contract number  
378 DEAC05-00OR22725. The authors thank Shuo Qian for his BioSANS tech-  
379 nical assistance and Georg Pabst for access to the GAP program. F.A.H  
380 acknowledges support from National Science Foundation grant No. MCB-  
381 1817929. M.D., M.H.L.N. and B.W.R. are supported by Ontario Graduate  
382 Scholarships. D.M. acknowledges the support of the Natural Sciences and  
383 Engineering Research Council of Canada (NSERC), [funding reference num-  
384 ber RGPIN-2018-04841] and the University of Windsor start-up funds.

## 385 **References**

- 386 [1] H. M. Evans, K. S. Bishop, On the existence of a hitherto unrecognized  
387 dietary factor essential for reproduction, *Science* 56 (1922) 650–651.
- 388 [2] R. Brigelius-Flohé, K. J. Davies, Is vitamin E an antioxidant, a reg-  
389 ulator of signal transduction and gene expression, or a ‘junk’ food?  
390 Comments on the two accompanying papers: “Molecular mechanism  
391 of  $\alpha$ -tocopherol action” by A. Azzi and “Vitamin E, antioxidant and



- 392 nothing more” by M. Traber, *Free Radical Biology and Medicine* 43  
393 (2007) 2–3.
- 394 [3] R. Brigelius-Flohé, Vitamin E: The shrew waiting to be tamed, *Free*  
395 *Radical Biology and Medicine* 46 (2009) 543–554.
- 396 [4] R. Brigelius-Flohé, F. Galli, Vitamin E: A vitamin still awaiting the de-  
397 tection of its biological function, *Molecular Nutrition and Food Research*  
398 54 (2010) 583–587.
- 399 [5] H. J. Kayden, M. G. Traber, Absorption, lipoprotein transport, and  
400 regulation of plasma concentrations of vitamin E in humans, *Journal of*  
401 *Lipid Research* 34 (1993) 343–358.
- 402 [6] M. G. Traber, Vitamin E Regulatory Mechanism, *Annual Review of*  
403 *Nutrition* 27 (2007) 347–362.
- 404 [7] Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and  
405 Carotenoids, 2000.
- 406 [8] M. G. Traber, J. Atkinson, Vitamin E, antioxidant and nothing more,  
407 *Free Radical Biology & Medicine* 43 (2007) 4–15.
- 408 [9] E. Niki, Role of vitamin E as a lipid-soluble peroxy radical scavenger:  
409 in vitro and in vivo evidence, *Free Radical Biology and Medicine* 66  
410 (2014) 3–12.
- 411 [10] K. Gohil, V. T. Vasu, C. E. Cross, Dietary  $\alpha$ -tocopherol and neuro-  
412 muscular health: Search for optimal dose and molecular mechanisms  
413 continues!, *Molecular Nutrition and Food Research* 54 (2010) 693–709.

- 414 [11] J. Atkinson, R. F. Epanand, R. M. Epanand, Tocopherols and tocotrienols  
415 in membranes: A critical review, *Free Radical Biology and Medicine* 44  
416 (2008) 739–764.
- 417 [12] H. Vatanparast, J. L. Adolphe, S. J. Whiting, Socio-economic status and  
418 vitamin/ mineral supplement use in Canada., *Health reports / Statistics*  
419 *Canada, Canadian Centre for Health Information* 21 (2010) 19–25.
- 420 [13] E. A. Klein, I. M. Thompson, C. M. Tangen, J. J. Crowley, S. Lucia, P. J.  
421 Goodman, L. M. Minasian, L. G. Ford, H. L. Parnes, J. M. Gaziano,  
422 D. D. Karp, M. M. Lieber, P. J. Walther, L. Klotz, J. K. Parsons, J. L.  
423 Chin, A. K. Darke, S. M. Lippman, G. E. Goodman, F. L. Meyskens,  
424 L. H. Baker, Vitamin E and the risk of prostate cancer: The selenium  
425 and vitamin E cancer prevention trial (SELECT), *JAMA - Journal of*  
426 *the American Medical Association* 306 (2011) 1549–1556.
- 427 [14] S. M. Lippman, E. A. Klein, P. J. Goodman, M. S. Lucia, I. M. Thomp-  
428 son, L. G. Ford, H. L. Parnes, L. M. Minasian, J. M. Gaziano, J. A.  
429 Hartline, J. K. Parsons, J. D. Bearden, E. D. Crawford, G. E. Good-  
430 man, J. Claudio, E. Winquist, E. D. Cook, D. D. Karp, P. Walther,  
431 M. M. Lieber, A. R. Kristal, A. K. Darke, K. B. Arnold, P. A. Ganz,  
432 R. M. Santella, D. Albanes, P. R. Taylor, J. L. Probstfield, T. J. Jagpal,  
433 J. J. Crowley, F. L. Meyskens, L. H. Baker, C. A. Coltman, Effect of  
434 Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers,  
435 *Jama* 301 (2009) 39.
- 436 [15] Y. C. Li, M. J. Park, S. K. Ye, C. W. Kim, Y. N. Kim, Elevated levels  
437 of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis

- 438 sensitivity induced by cholesterol-depleting agents, *American Journal of*  
439 *Pathology* 168 (2006) 1107–1118.
- 440 [16] K. Simons, M. J. Gerl, Revitalizing membrane rafts: New tools and  
441 insights, *Nature Reviews Molecular Cell Biology* 11 (2010) 688–699.
- 442 [17] D. Lingwood, K. Simons, Lipid Rafts As a Membrane-Organizing Prin-  
443 ciple, *Science* 327 (2010) 46–50.
- 444 [18] N. Resnik, U. Repnik, M. E. Kreft, K. Sepčić, P. Maček, B. Turk,  
445 P. Veranič, Highly selective anti-cancer activity of cholesterol-interacting  
446 agents methyl- $\beta$ -cyclodextrin and ostreolysin a/pleurotolysin b protein  
447 complex on urothelial cancer cells, *PLOS ONE* 10 (2015) 1–19.
- 448 [19] A. Badana, M. Chintala, G. Varikuti, N. Pudi, S. Kumari, V. R. Kap-  
449 pala, R. R. Malla, Lipid raft integrity is required for survival of triple  
450 negative breast cancer cells, *Journal of Breast Cancer* 19 (2016) 372–384.
- 451 [20] C. S. Yang, N. Suh, A. N. T. Kong, Does vitamin E prevent or promote  
452 cancer?, *Cancer Prevention Research* 5 (2012) 701–705.
- 453 [21] G. X. Li, M. J. Lee, A. B. Liu, Z. Yang, Y. Lin, W. J. Shih, C. S. Yang,  
454  $\delta$ -tocopherol is more active than  $\alpha$ - or  $\gamma$ -tocopherol in inhibiting lung  
455 tumorigenesis in Vivo, *Cancer Prevention Research* 4 (2011) 404–413.
- 456 [22] J. Ju, S. C. Picinich, Z. Yang, Y. Zhao, N. Suh, A. N. Kong, C. S. Yang,  
457 Cancer-preventive activities of tocopherols and tocotrienols, *Carcino-*  
458 *genesis* 31 (2010) 533–542.

- 459 [23] C. Eggeling, C. Ringemann, R. Medda, G. Schwarzmann, K. Sandhoff,  
460 S. Polyakova, V. N. Belov, B. Hein, C. Von Middendorff, A. Schönle,  
461 S. W. Hell, Direct observation of the nanoscale dynamics of membrane  
462 lipids in a living cell, *Nature* 457 (2009) 1159–1162.
- 463 [24] E. L. Elson, E. Fried, J. E. Dolbow, G. M. Genin, Phase Separation in  
464 Biological Membranes: Integration of Theory and Experiment, *Annual*  
465 *Review of Biophysics* 39 (2010) 207–226.
- 466 [25] J. D. Nickels, S. Chatterjee, C. B. Stanley, S. Qian, X. Cheng, D. A. A.  
467 Myles, R. F. Standaert, J. G. Elkins, J. Katsaras, The in vivo structure  
468 of biological membranes and evidence for lipid domains, *PLOS Biology*  
469 15 (2017) 1–22.
- 470 [26] G. W. Feigenson, Phase boundaries and biological membranes, *Annual*  
471 *Review of Biophysics and Biomolecular Structure* 36 (2007) 63–77.
- 472 [27] G. W. Feigenson, Phase diagrams and lipid domains in multicomponent  
473 lipid bilayer mixtures, *Biochimica et Biophysica Acta - Biomembranes*  
474 1788 (2009).
- 475 [28] D. Marquardt, F. A. Heberle, J. D. Nickels, G. Pabst, J. Katsaras, On  
476 scattered waves and lipid domains: detecting membrane rafts with X-  
477 rays and neutrons, *Soft Matter* 11 (2015) 9055–9072.
- 478 [29] G. W. Feigenson, J. T. Buboltz, Ternary phase diagram of dipalmitoyl-  
479 PC/dilauroyl-PC/cholesterol: Nanoscopic domain formation driven by  
480 cholesterol, *Biophysical Journal* 80 (2001) 2775–2788.

- 481 [30] S. L. Veatch, S. L. Keller, Separation of Liquid Phases in Giant Vesicles of Ternary Mixtures of Phospholipids and Cholesterol, *Biophysical Journal* 85 (2003) 3074–3083.
- 482  
483
- 484 [31] F. A. Heberle, G. W. Feigenson, Phase separation in lipid membranes, *Cold Spring Harbor Perspectives in Biology* 3 (2011) 1–13.
- 485
- 486 [32] S. L. Veatch, S. L. Keller, Seeing spots: Complex phase behavior in simple membranes, *Biochimica et Biophysica Acta - Molecular Cell Research* 1746 (2005) 172–185.
- 487  
488
- 489 [33] P. Heftberger, B. Kollmitzer, A. A. Rieder, H. Amenitsch, G. Pabst, In situ determination of structure and fluctuations of coexisting fluid membrane domains, *Biophysical Journal* 108 (2015) 854–862.
- 490  
491
- 492 [34] F. A. Heberle, R. S. Petruzielo, J. Pan, P. Drazba, N. Kučerka, R. F. Standaert, G. W. Feigenson, J. Katsaras, Bilayer thickness mismatch controls raft size in model membranes, *Journal of the American Chemical Society* 135 (2013) 6853–6859.
- 493  
494  
495
- 496 [35] O. Arnold, J. C. Bilheux, J. M. Borreguero, A. Buts, S. I. Campbell, L. Chapon, M. Doucet, N. Draper, R. Ferraz Leal, M. A. Gigg, V. E. Lynch, A. Markvardsen, D. J. Mikkelsen, R. L. Mikkelsen, R. Miller, K. Palmen, P. Parker, G. Passos, T. G. Perring, P. F. Peterson, S. Ren, M. A. Reuter, A. T. Savici, J. W. Taylor, R. J. Taylor, R. Tolchenov, W. Zhou, J. Zikovsky, Mantid - Data analysis and visualization package for neutron scattering and  $\mu$  SR experiments, *Nuclear Instruments and*
- 497  
498  
499  
500  
501  
502

- 503       Methods in Physics Research, Section A: Accelerators, Spectrometers,  
504       Detectors and Associated Equipment 764 (2014) 156–166.
- 505 [36] S. R. Kline, Reduction and analysis of SANS and USANS data using  
506       IGOR Pro, *Journal of Applied Crystallography* 39 (2006) 895–900.
- 507 [37] O. Glatter, O. Kratky, Chapter 2, in: *Small Angle X-Ray Scattering*,  
508       Academic Press, New York, 1982.
- 509 [38] J. Pencer, V. N. Anghel, N. Kučerka, J. Katsaras, Scattering from  
510       laterally heterogeneous vesicles. I. Model-independent analysis, *Journal*  
511       *of Applied Crystallography* 39 (2006) 791–796.
- 512 [39] P. V. Konarev, V. V. Volkov, A. V. Sokolova, M. H. Koch, D. I. Svergun,  
513       PRIMUS: A Windows PC-based system for small-angle scattering data  
514       analysis, *Journal of Applied Crystallography* 36 (2003) 1277–1282.
- 515 [40] G. Pabst, M. Rappolt, H. Amenitsch, P. Lagner, Structural information  
516       from multilamellar liposomes at full hydration: Full q-range fitting  
517       with high quality x-ray data, *Physical Review E* 52 (2000) 4000–4009.
- 518 [41] G. Pabst, J. Katsaras, V. A. Raghunathan, M. Rappolt, Structure and  
519       interactions in the anomalous swelling regime of phospholipid bilayers,  
520       *Langmuir* 19 (2003) 1716–1722.
- 521 [42] T. M. Konyakhina, G. W. Feigenson, Phase diagram of a polyunsatu-  
522       rated lipid mixture: Brain sphingomyelin/1-stearoyl-2-docosahexaenoyl-  
523       sn-glycero-3-phosphocholine/cholesterol, *Biochimica et Biophysica Acta*  
524       - *Biomembranes* 1858 (2016) 153–161.

- 525 [43] M. I. Angelova, S. Soléau, P. Méléard, F. Faucon, P. Bothorel, Preparation  
526 of giant vesicles by external AC electric fields. Kinetics and appli-  
527 cations., in: C. Helm, M. Lösche, H. Möhwald (Eds.), Trends in Colloid  
528 and Interface Science VI, Springer, 1992, pp. 127–131.
- 529 [44] T. Baumgart, G. Hunt, E. R. Farkas, W. W. Webb, G. Feigenson, Fluorescence  
530 probe partitioning between Lo /Ld phases in lipid membranes,  
531 *Biochim Biophys Acta*. 1768 (2007) 2182–2194.
- 532 [45] E. Baykal-Caglar, E. Hassan-Zadeh, B. Saremi, J. Huang, Preparation  
533 of giant unilamellar vesicles from damp lipid film for better lipid com-  
534 positional uniformity, *Biochimica et Biophysica Acta - Biomembranes*  
535 1818 (2012) 2598–2604.
- 536 [46] J. Heuvingh, S. Bonneau, Asymmetric oxidation of giant vesicles triggers  
537 curvature-associated shape transition and permeabilization, *Biophysical*  
538 *Journal* 97 (2009) 2904–2912.
- 539 [47] P. Heftberger, B. Kollmitzer, F. A. Heberle, J. Pan, M. Rappolt,  
540 H. Amenitsch, N. Kučerka, J. Katsaras, G. Pabst, Global small-angle  
541 X-ray scattering data analysis for multilamellar vesicles: the evolution of  
542 the scattering density profile model, *Journal of Applied Crystallography*  
543 47 (2014) 173–180.
- 544 [48] N. Kučerka, M. P. Nieh, J. Katsaras, Fluid phase lipid areas and bi-  
545 layer thicknesses of commonly used phosphatidylcholines as a function  
546 of temperature, *Biochimica et Biophysica Acta - Biomembranes* 1808  
547 (2011) 2761–2771.

- 548 [49] D. Marquardt, J. A. Williams, N. Kučerka, J. Atkinson, S. R. Wassall,  
549 J. Katsaras, T. A. Harroun, Tocopherol Activity Correlates with Its Lo-  
550 cation in a Membrane: A New Perspective on the Antioxidant Vitamin  
551 E, *Journal of the American Chemical Society* 135 (2013) 7523–7533.
- 552 [50] D. Marquardt, J. A. Williams, J. J. Kinnun, N. Kučerka, J. Atkinson,  
553 S. R. Wassall, J. Katsaras, T. A. Harroun, Dimyristoyl Phosphatidyl-  
554 choline: A Remarkable Exception to  $\alpha$ -Tocopherol’s Membrane Pres-  
555 ence, *Journal of the American Chemical Society* 136 (2014) 203–210.
- 556 [51] D. Marquardt, N. Kučerka, J. Katsaras, T. A. Harroun,  $\alpha$ -tocopherols  
557 location in membranes is not affected by their composition, *Langmuir*  
558 31 (2015) 4464–4472.
- 559 [52] F. A. Heberle, M. Doktorova, S. L. Goh, R. F. Standaert, J. Katsaras,  
560 G. W. Feigenson, Hybrid and nonhybrid lipids exert common effects on  
561 membrane raft size and morphology, *Journal of the American Chemical*  
562 *Society* 135 (2013) 14932–14935.
- 563 [53] D. Bolmatov, W. T. McClintic, G. Taylor, C. B. Stanley, C. Do, C. P.  
564 Collier, Z. Leonenko, M. O. Lavrentovich, J. Katsaras, Deciphering  
565 melatonin-stabilized phase separation in phospholipid bilayers, *Lang-*  
566 *muir* 35 (2019) 12236–12245.
- 567 [54] K. Simons, J. L. Sampaio, *Membrane organization and lipid rafts*, 2011.
- 568 [55] J. H. Lorent, B. Diaz-Rohrer, X. Lin, K. Spring, A. A. Gorfe, K. R. Lev-  
569 ental, I. Levental, Structural determinants and functional consequences



- 570 of protein affinity for membrane rafts, *Nature Communications* 8 (2017)  
571 1219.
- 572 [56] M. Schick, Membrane heterogeneity: Manifestation of a curvature-  
573 induced microemulsion, *Phys. Rev. E* 85 (2012) 031902.
- 574 [57] J. J. Amazon, S. L. Goh, G. W. Feigenson, Competition between line  
575 tension and curvature stabilizes modulated phase patterns on the surface  
576 of giant unilamellar vesicles: A simulation study, *Phys. Rev. E* 87 (2013)  
577 022708.
- 578 [58] S. L. Veatch, O. Soubias, S. L. Keller, K. Gawrisch, Critical fluctuations  
579 in domain-forming lipid mixtures, *Proceedings of the National Academy  
580 of Sciences* 104 (2007) 17650–17655.
- 581 [59] R. Brewster, P. Pincus, S. Safran, Hybrid lipids as a biological surface-  
582 active component, *Biophysical Journal* 97 (2009) 1087 – 1094.
- 583 [60] H. S. Muddana, H. H. Chiang, P. J. Butler, Tuning membrane phase  
584 separation using nonlipid amphiphiles, *Biophysical Journal* 102 (2012)  
585 489–497.
- 586 [61] S.-T. Yang, V. Kiessling, L. K. Tamm, Line tension at lipid phase bound-  
587 aries as driving force for HIV fusion peptide-mediated fusion, *Nature  
588 Communications* 7 (2016) 11401.
- 589 [62] A. J. García-Sáez, S. Chiantia, P. Schwille, Effect of line tension on the  
590 lateral organization of lipid membranes, *Journal of Biological Chemistry*  
591 282 (2007) 33537–33544.

- 592 [63] J. D. Nickels, X. Cheng, B. Mostofian, C. Stanley, B. Lindner, F. A.  
593 Heberle, S. Perticaroli, M. Feygenson, T. Egami, R. F. Standaert, J. C.  
594 Smith, D. A. Myles, M. Ohl, J. Katsaras, Mechanical Properties of  
595 Nanoscopic Lipid Domains, *Journal of the American Chemical Society*  
596 137 (2015) 15772–15780.
- 597 [64] D. Marsh, A. Watts, P. F. Knowles, Evidence for phase boundary lipid.  
598 permeability of tempo-choline into dimyristoylphosphatidylcholine vesi-  
599 cles at the phase transition, *Biochemistry* 15 (1976) 3570–3578. PMID:  
600 182212.
- 601 [65] L. Cruzeiro-Hansson, O. G. Mouritsen, Passive ion permeability of lipid  
602 membranes modelled via lipid-domain interfacial area, *BBA - Biomem-  
603 branes* 944 (1988) 63–72.
- 604 [66] R. M. Cordeiro, Molecular Structure and Permeability at the Inter-  
605 face between Phase-Separated Membrane Domains, *Journal of Physical  
606 Chemistry B* 122 (2018) 6954–6965.
- 607 [67] T. M. Tsubone, H. C. Junqueira, M. S. Baptista, R. Itri, Contrast-  
608 ing roles of oxidized lipids in modulating membrane microdomains,  
609 *Biochimica et Biophysica Acta - Biomembranes* 1861 (2019) 660–669.
- 610 [68] R. Volinsky, R. Paananen, P. K. J. Kinnunen, Oxidized phosphatidyl-  
611 cholines promote phase separation of cholesterol-sphingomyelin do-  
612 mains, *Biophysical Journal* 103 (2012) 247–254.